Aptamer therapeutics useful in the treatment of complement-related disorders

Abstract

The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.

1 - 33 . (canceled) 
     
     
         34 . A compound comprising the nucleotide sequence of SEQ ID NO: 2, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60 or 66 or a pharmaceutically acceptable salt thereof. 
     
     
         35 . The compound or pharmaceutically acceptable salt thereof of  claim 34  conjugated to a polyethylene glycol moiety. 
     
     
         36 . The composition of  claim 35  wherein the polyethylene glycol moiety comprises a molecular weight greater than 10 kDa. 
     
     
         37 . The composition of  claim 35  wherein the polyethylene glycol moiety comprises a molecular weight of 20 kDa. 
     
     
         38 . The compound or pharmaceutically acceptable salt thereof of  claim 37  wherein the nucleotide sequence is SEQ ID NO: 66. 
     
     
         39 . A pharmaceutical composition comprising a therapeutically effective amount of the compound or salt of  claim 34  and a pharmaceutically acceptable carrier or vehicle. 
     
     
         40 . A method for treating a C5 complement protein, C5a and/or C5b-9 mediated disorder, the method comprising administering to a patient in need thereof a therapeutically effective amount of the compound or pharmaceutically acceptable salt of the compound of  claim 34 . 
     
     
         41 . The method of  claim 40  wherein the disorder is complement mediated ocular tissue damage.